AlphaMark Advisors LLC lessened its holdings in Enanta Pharmaceuticals (NASDAQ:ENTA) by 26.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 14,715 shares of the biotechnology company’s stock after selling 5,235 shares during the quarter. AlphaMark Advisors LLC owned 0.08% of Enanta Pharmaceuticals worth $1,191,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Wells Fargo & Company MN boosted its holdings in Enanta Pharmaceuticals by 36.7% in the third quarter. Wells Fargo & Company MN now owns 18,197 shares of the biotechnology company’s stock worth $852,000 after acquiring an additional 4,886 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Enanta Pharmaceuticals by 1.4% in the third quarter. Dimensional Fund Advisors LP now owns 562,394 shares of the biotechnology company’s stock worth $26,320,000 after acquiring an additional 7,617 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in Enanta Pharmaceuticals in the fourth quarter worth about $1,191,000. First Manhattan Co. boosted its holdings in Enanta Pharmaceuticals by 14.5% in the fourth quarter. First Manhattan Co. now owns 1,084,200 shares of the biotechnology company’s stock worth $63,620,000 after acquiring an additional 137,100 shares in the last quarter. Finally, BlackRock Inc. boosted its holdings in Enanta Pharmaceuticals by 4.3% in the fourth quarter. BlackRock Inc. now owns 2,343,593 shares of the biotechnology company’s stock worth $137,521,000 after acquiring an additional 97,054 shares in the last quarter. 74.03% of the stock is owned by institutional investors and hedge funds.

In other news, Treasurer Paul J. Mellett sold 9,000 shares of the firm’s stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $86.48, for a total value of $778,320.00. Following the completion of the transaction, the treasurer now directly owns 96,458 shares in the company, valued at $8,341,687.84. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Nathalie Adda sold 4,225 shares of the firm’s stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $85.58, for a total value of $361,575.50. Following the completion of the transaction, the vice president now owns 10,225 shares of the company’s stock, valued at $875,055.50. The disclosure for this sale can be found here. Company insiders own 10.56% of the company’s stock.

Several equities research analysts have weighed in on the company. Zacks Investment Research raised Enanta Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $111.00 price target for the company in a report on Thursday, May 3rd. Royal Bank of Canada raised their price target on Enanta Pharmaceuticals to $78.00 and gave the stock a “sector perform” rating in a report on Thursday, February 8th. JPMorgan Chase downgraded Enanta Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Thursday, February 8th. BidaskClub raised Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, March 14th. Finally, ValuEngine raised Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, April 2nd. Three equities research analysts have rated the stock with a hold rating, one has given a buy rating and three have issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $63.60.

Shares of Enanta Pharmaceuticals opened at $106.12 on Friday, MarketBeat.com reports. Enanta Pharmaceuticals has a 52-week low of $104.32 and a 52-week high of $105.99. The stock has a market capitalization of $2.02 billion, a PE ratio of 116.62 and a beta of 1.05.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.53 by $0.08. Enanta Pharmaceuticals had a return on equity of 18.50% and a net margin of 31.60%. The firm had revenue of $44.00 million during the quarter, compared to analysts’ expectations of $40.77 million. During the same period last year, the business posted ($0.28) earnings per share. The company’s revenue for the quarter was up 388.9% compared to the same quarter last year. research analysts anticipate that Enanta Pharmaceuticals will post 3.16 EPS for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals (NASDAQ:ENTA).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.